tezepelumab
Sponsor Astrazeneca PLC · listed as AZN
tezepelumab is a drug asset sponsored by Astrazeneca PLC, listed as AZN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Feb 7, 2028 (day precision, medium confidence), tied to trial NCT07363642. That trial is in Phase 3 and currently recruiting, studying Severe Asthma. It appears across 5 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for tezepelumab in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06740045 | Phase 3 | Not yet recruiting | 2025-03 | Experimental | Dr. Andrew Thamboo, MD | Asthma; Chronic Rhinosinusitis With Nasal Polyps |
| NCT07363642 catalyst | Phase 3 | Recruiting | 2028-02-07 | Experimental | AstraZeneca | Severe Asthma |
| NCT06023589 | Phase 3 | Recruiting | 2028-05-31 | Experimental | AstraZeneca | Asthma |
| NCT07302516 | Phase 3 | Not yet recruiting | 2028-12 | Experimental | Qilu Pharmaceutical Co., Ltd. | Asthma |
| NCT07013123 | Phase 3 | Not yet recruiting | 2029-08-18 | Experimental | University Hospital, Montpellier | Severe Asthma; Allergy to House Dust Mites |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AZN catalysts